Safety of switching biologics and their interchangeability

Notice Santécom: 126814

A significant increase in the use of biologics could create an untenable financial strain on public drug insurance plans, which could greatly compromise access to innovative therapies. MSSS therefore asked INESSS to produce a state-of-knowledge report on the risks associated with switching biologics and their interchangeability.

This work has allowed for the identification of specific populations or biologics for which very little or no data are available regarding the safety of switching the biologic, and the significant concerns that clinicians have about non-medical switching.

Conducting adequate clinical studies would be useful to better determine the impact of switching between biologics.